Jim is a Principal Scientist in the Global Pathology and Investigative Toxicology group in Drug Safety R&D at Pfizer where he has been since 2000. Since receiving his BSc in Biology from Old Dominion University in 1986, he has worked 10 years in academic research (University of Virginia) and 20+ years in biopharma research (Pfizer, Wyeth) in a wide variety of research fields including neuroscience, deafness, cardiovascular/metabolic diseases, and oncology. The Investigative Tox group is a small team that does deep dive investigations into specific toxicity issues and builds safety de-risking models for programs across all therapeutic areas. As the imaging technical expert, he specializes in imaging-based assays for target identification/evaluation, drug activity/biodistribution/cell viability/toxicity. He has expertise in all phases of histotechnology (cell/tissue processing, sectioning, staining, immunohistochemistry); microscopy (fluorescence, confocal, live cell, multidimensional, 3D, HCS); in vitro assays (intracellular trafficking, endocytosis, angiogenesis, ROS, wound healing, NETosis, transfection, knockdown); and image analysis on cells or tissue using multiple platforms. His recent work has focused heavily on building 3D organoid and multi-physiological-system (MPS) models for safety and tox endpoints. He has been a member of SBI2 since 2015 and find it to be an invaluable resource for networking and keeping up with the latest HCS advances and technology.